“Partner” Redefined
At Alexza, partnerships come in many shapes and sizes, they can be traditional or non-traditional, and satisfy needs on many different levels. Our first goal in all our partnerships is to create a win-win environment for the partnership to flourish. Developing partnerships that build a pipeline of Staccato-based products with significant clinical and commercial value is a key component of our business strategy.
Through licensing relationships, research collaborations and strategic alliances that complement and extend the Staccato® technology, Alexza is interested in developing partnerships that have the potential to create innovative products and improve patients' lives.
Alexza will maximize its pipeline through strategic partnering to optimize its research and development assets, and strengthen ongoing internal development capabilities. We welcome the opportunity to work with partners on developing their molecule(s) of choice (known actives or NCEs) as possible Staccato-based products. Quick feasibility studies can determine if a viable developmental path is achievable for compounds of interest.
Partnering is integral to our business model and success. Our aim is to form strategic collaborations that advance novel products to the patients that need them. In order to ensure patients access to our products in any territory in the world, we actively seek co-development and commercialization partners around the globe.
To discuss partnership opportunities, please contact our
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
Our Partners:
Autoliv North America
Through a unique partnering agreement, Autoliv North America manufactures the chemical heat packages for our single-dose Staccato system. Autoliv North America, a subsidiary of Sweden-based Autoliv Inc., is a leader in the design and manufacture of energetic materials for its state-of-the-art automotive safety systems.
www.autoliv.com
Cypress Biosciences / Royalty Pharma
Through a licensing agreement, Cypress Biosciences has rights to develop Staccato® Nicotine for smoking cessation. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking by delivering nicotine via inhalation without the harmful side effects associated with cigarettes. Cypress Biosciences was acquired by Royalty Pharma in 2010.
Grupo Ferrer International, S.A.
Through a commercial partnership for ADASUVE™ (Staccato® Loxapine), Alexza's lead product candidate, Group Ferrer will commercialize the product in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Grupo Ferrer is a privately-held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain. Founded in 1959, the group today encompasses 45 companies with activities in Europe, Latin America, Africa, Middle East, Asia and the United States. In total, Grupo Ferrer's human healthcare products are being commercialized in 93 countries through 26 direct subsidiaries, and 70 partners and distributors.
www.ferrergrupo.com
|
